Press Release

Exciting new NGS based service facilitates analysis for CRISPR/Cas9 mutations with highest accuracy possible

Ebersberg, Germany, 13th November 2019

Eurofins Genomics has just launched a next generation sequencing (NGS) service that enables customers to analyse mutations introduced by the CRISPR/Cas9 system. This new service delivers highly reliable results with the most complete coverage, quickly and conveniently.

Scientists agree that accuracy is crucial in gene editing. Such accuracy is sometimes limited when using CRISPR/Cas9. The new "**INVIEW CRISPR Check**" service therefore ensures that researchers have full visibility of the editing efficiency of their genomic target and the service can also be used to rule out predicted off-target regions. This can be done in various stages of the genome editing process, enabling scientists to have informational control throughout their experiment. Moreover, scientists already applying this revolutionary technology in their laboratories can ensure that their research and development studies contain no unwanted mutations in their target regions.

The applications of the INVIEW CRISPR Check range from the evaluation of the editing system by analysing mutation efficiencies and type of mutation to the identification, through screenings, of promising knock-out candidates. Like all of the services of the Eurofins Genomics´ INVIEW product category offerings, customers only need to provide a single sample which allows for a cost-effective service, with prices starting from 46,99 Euro/sample.

Dr. Michael Hadem, (Senior Director Genomics Europe): *"The CRISPR/Cas9 system has revolutionised gene-editing by making it easier, faster and more versatile than ever before. We are therefore proud that we can support researchers to achieve their goals with our enhanced CRISPR portfolio."*

The new **INVIEW CRISPR Check** is available at the Eurofins Genomics web shop at:

https://www.eurofinsgenomics.eu/en/next-generation-sequencing/ngs-built-for-you/inview-crispr-check

INVIEW CRISPR Check - Application overview

- Evaluation of CRISPR/Cas9 induced mutations in target genes with high sequence coverage and low limit of detection (LOD)
- Screening of CRISPR/Cas9 edited samples for promising candidates
- Evaluation of a newly developed editing system by analysing mutation efficiency and type of mutations
- Analysis of on-target and / or (predicted) off-target loci for exclusion of side-effects

Eurofins Genomics Europe Shared Services GmbH
Anzinger Straße 7 a
85560 Ebersberg

Tel.: +49 7531 816068
Fax: +49 8092 21084
Email: info-eu@eurofins.com

Managing Director: Dr. Michael Hadem

Register Court Munich HRB 245243

For Further Information:

Media Contact:
Julian Schlossmacher
Head of Marketing and Communications Europe
Eurofins Genomics
+49 8092 8289 925
julianschlossmacher@eurofins.com
Eurofins Genomics Website: www.eurofinsgenomics.com

Notes to Editors:

About Eurofins Genomics

Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, the United States and Asia, is an internationally leading provider of DNA sequencing services, next generation sequencing services, genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The company's strength is its extensive customer base and high quality services in industrial scale for the life science industries and academic research institutions around the world. For further information, please visit our website at eurofinsgenomics.com.

Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.